Mekinist (trametinib) — Medica
Hairy Cell Leukemia
Initial criteria
- Patient has not been previously treated with a BRAF inhibitor therapy
- The medication will be used for relapsed/refractory disease
- The medication will be taken in combination with Tafinlar (dabrafenib)
Approval duration
1 year